Quantitative phenotypic and pathway profiling guides rational drug combination strategies

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Advances in target-based drug discovery strategies have enabled drug discovery groups in academia and industry to become very effective at generating molecules that are potent and selective against single targets. However, it has become apparent from disappointing results in recent clinical trials that a major challenge to the development of successful targeted therapies for treating complex multifactorial diseases is overcoming heterogeneity in target mechanism among patients and inherent or acquired drug resistance. Consequently, reductionist target directed drug-discovery approaches are not appropriately tailored toward identifying and optimizing multi-targeted therapeutics or rational drug combinations for complex disease. In this article, we describe the application of emerging high-content phenotypic profiling and analysis tools to support robust evaluation of drug combination performance following dose-ratio matrix screening. We further describe how the incorporation of high-throughput reverse phase protein microarrays with phenotypic screening can provide rational drug combination hypotheses but also confirm the mechanism-of-action of novel drug combinations, to facilitate future preclinical and clinical development strategies.

Original languageEnglish
Pages (from-to)118
JournalFrontiers in pharmacology
Volume5
DOIs
Publication statusPublished - 28 May 2014

Fingerprint Dive into the research topics of 'Quantitative phenotypic and pathway profiling guides rational drug combination strategies'. Together they form a unique fingerprint.

Cite this